Skip to main content
SpringerLink
Log in

What is New in Rhabdomyosarcoma Management in Children?

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Optimal management of rhabdomyosarcoma requires establishing the correct pathologic diagnosis, histologic sub-type, primary site, extent of disease (Stage), and extent of resection (Group). Based on these features, cooperative groups in North America and Europe have defined risk-adapted treatments that include surgery, chemotherapy, and usually radiotherapy. This article focuses on recent findings that can impact or have already impacted rhabdomyosarcoma treatment guidelines and highlights controversies that should be addressed in order to improve outcome for children with rhabdomyosarcoma.

Rhabdomyosarcoma is currently sub-classified in children based on histology into the favorable embryonal/botryoid/spindle cell types and the unfavorable alveolar form. Risk group assignment depends in part on histologic sub-type. Alveolar rhabdomyosarcoma is sometimes associated with chromosomal translocations, which impact clinical behavior. An important ongoing debate is whether molecular diagnostic tools to identify chromosomal translocations and/or define gene expression profiles should be used to sub-classify rhabdomyosarcoma rather than histology. Clinical trials continue to evaluate retrospective as well as prospective cohorts in order to carefully determine the impact of histology versus biologic features on outcome in the context of specific therapeutic regimens.

Most rhabdomyosarcoma recurrences involve the primary site or adjacent region. Cooperative groups continue to investigate new approaches to local control in order to reduce local recurrences and sequelae associated with local therapy. Delaying primary resection until after chemotherapy has started appears to increase the number of tumors that can be completely resected with acceptable morbidity in some primary sites. Radiation dose reductions following delayed primary resection have been investigated. Although outcomes appear similar to the conventional approach of full-dose radiotherapy without delayed primary resection, long-term effects of the two approaches have not been rigorously compared. Early evidence suggests that newer methods of delivering radiotherapy, including intensity-modulated radiotherapy (IMRT), proton beam radiotherapy, and brachytherapy maintain efficacy but may reduce long-term sequelae compared with 3-dimensional conformal radiotherapy.

Chemotherapy regimens defined by the cooperative groups vary by risk group. The most commonly used regimens include vincristine and dactinomycin in combination with an alkylating agent, either cyclophosphamide or ifosfamide. In order to improve outcomes, recent clinical trials have introduced new chemotherapeutic agents (e.g. topotecan, carboplatin, or epirubicin) into the treatment regimens. However, outcomes have not been significantly impacted. Novel chemotherapy administration schedules have been tested in patients with metastatic rhabdomyosarcoma, including interval compressed dosing or maintenance therapy, and may be promising. Molecularly targeted agents are currently under investigation in combination with chemotherapy for patients with recurrent or metastatic rhabdomyosarcoma. It is hoped that these novel agents will benefit all patients with rhabdomyosarcoma in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Ries LAG, Smith MA, Gurney JG, et al., editors. cancer incidence and survival among children and adolescents: United States SEER Program 1975–1999. Bethesda (MD): National Cancer Institute, SEER Program, 1999

    Google Scholar 

  2. Walterhouse D, Watson A. Optimal management strategies for rhabdomyosarcoma in children. Paediatr Drugs 2007; 9 (6): 391–400

    Article  PubMed  Google Scholar 

  3. Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 2006 Aug 20; 24 (24): 3844–51

    Article  PubMed  Google Scholar 

  4. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyo-sarcoma Study-I: a final report. Cancer 1988 Jan 15; 61 (2): 209–20

    Article  PubMed  CAS  Google Scholar 

  5. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001 Jun 15; 19 (12): 3091–102

    PubMed  CAS  Google Scholar 

  6. Lawrence W, Gehan EA, Hays DM, et al. Prognostic significance of staging factors of the UICC Staging System in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987 Jan; 5 (1): 46–54

    PubMed  Google Scholar 

  7. European Paediatric Soft Tissue Sarcoma Study Group. Combination chemotherapy in treating young patients with nonmetastatic rhabdomyosarcoma [ClinicalTrials.gov identifier NCT00379457]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.dinicaltrials.gov [Accessed 2012 Sep 24]

  8. Newton Jr WA, Gehan EA, Webber BL, et al. Classification of rhabdomyo-sarcomas and related sarcomas: pathologic aspects and proposal for a new classification — an Intergroup Rhabdomyosarcoma Study. Cancer 1995 Sep 15; 76 (6): 1073–85

    Article  PubMed  Google Scholar 

  9. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001 May; 14 (5): 506–14

    Article  PubMed  CAS  Google Scholar 

  10. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophos-phamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol 2009 Nov 1; 27 (31): 5182–8

    Article  PubMed  CAS  Google Scholar 

  11. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2011 Apr 1; 29 (10): 1312–8

    Article  PubMed  CAS  Google Scholar 

  12. Barr FG, Smith LM, Lynch JC, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children’s Oncology Group. J Mol Diagn 2006 May; 8 (2): 202–8

    Article  PubMed  CAS  Google Scholar 

  13. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol 2002 Jun 1; 20 (11): 2672–9

    Article  PubMed  CAS  Google Scholar 

  14. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006 Jul 15; 66 (14): 6936–46

    Article  PubMed  CAS  Google Scholar 

  15. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma: genotypic and phenotypic determinants of diagnosis — a report from the Children’s Oncology Group. Am J Pathol 2009 Feb; 174 (2): 550–64

    Article  PubMed  CAS  Google Scholar 

  16. Davicioni E, Anderson JR, Buckley JD, et al. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group. J Clin Oncol 2010 Mar 1; 28 (7): 1240–6

    Article  PubMed  CAS  Google Scholar 

  17. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010 May 1; 28 (13): 2151–8

    Article  PubMed  Google Scholar 

  18. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol 2010 May 1; 28 (13): 2126–8

    Article  PubMed  Google Scholar 

  19. Anderson JR, Barr FG, Hawkins DS, et al. Fusion-negative alveolar rhab-domyosarcoma: modification of risk stratification is premature. J Clin Oncol 2010 Oct 10; 28 (29): e587–8; author reply e9–90

    Article  PubMed  Google Scholar 

  20. Stegmaier S, Poremba C, Schaefer KL, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer 2011 Sep; 57 (3): 406–14

    Article  PubMed  Google Scholar 

  21. Kodet R, Newton Jr WA, Hamoudi AB, et al. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features: a report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol 1993 May; 17 (5): 443–53

    Article  PubMed  CAS  Google Scholar 

  22. Qualman S, LynchJ, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer 2008 Dec 1; 113 (11): 3242–7

    Article  PubMed  Google Scholar 

  23. Ferrari A, Miceli R, Meazza C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 2010 Mar 10; 28 (8): 1322–8

    Article  PubMed  Google Scholar 

  24. Rodeberg DA, Stoner JA, Garcia-Henriquez N, et al. Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the children’s oncology group. Cancer. Epub 2010 Dec 14

  25. Reichek JL, Duan F, Smith LM, et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. Clin Cancer Res 2011 Mar 15; 17 (6): 1463–73

    Article  PubMed  CAS  Google Scholar 

  26. Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology — SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005 Apr 20; 23 (12): 2618–28

    Article  PubMed  Google Scholar 

  27. Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. Cancer 2007 Dec 1; 110 (11): 2561–7

    Article  PubMed  Google Scholar 

  28. Raney RB, Stoner JA, Walterhouse DO, et al. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study-IV, 1991–1997. Pediatr Blood Cancer 2004 Jun; 42 (7): 618–25

    Article  PubMed  Google Scholar 

  29. Blakely ML, Lobe TE, Anderson JR, et al. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg 1999 May; 34 (5): 736–41; discussion 41–2

    Article  PubMed  CAS  Google Scholar 

  30. Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 2001 Aug; 10 (3): 146–52

    Article  PubMed  CAS  Google Scholar 

  31. Kayton ML, Delgado R, Busam K, et al. Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients. Cancer 2008 May 1; 112 (9): 2052–9

    Article  PubMed  Google Scholar 

  32. De Corti F, Dall’Igna P, Bisogno G, et al. Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer 2009 Jan; 52 (1): 51–4

    Article  PubMed  Google Scholar 

  33. Rodeberg DA, Wharam MD, Lyden E, et al. Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): a report from the Children’s Oncology Group (COG) [abstract no. 9504]. J Clin Oncol 2010; 28 (15 Suppl.): 9504

    Google Scholar 

  34. Seitz G, Dantonello TM, Int-Veen C, et al. Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma trial CWS-96. Pediatr Blood Cancer 2011 May; 56 (5): 718–24

    Article  PubMed  Google Scholar 

  35. Raney B, Stoner J, Anderson J, et al. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991–1997: a report from the Children’s Oncology Group. J Pediatr Surg 2010 Nov; 45 (11): 2160–8

    Article  PubMed  Google Scholar 

  36. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995 Mar; 13 (3): 610–30

    PubMed  CAS  Google Scholar 

  37. Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 2009 Mar 20; 27 (9): 1446–55

    Article  PubMed  CAS  Google Scholar 

  38. Modritz D, Ladenstein R, Potschger U, et al. Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr 2005 Mar; 117 (5–6): 196–209

    Article  Google Scholar 

  39. Cecchetto G, Carretto E, Bisogno G, et al. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: a report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer 2008 Nov; 51 (5): 593–7

    Article  PubMed  Google Scholar 

  40. Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 2011 Jul 15; 57 (1): 76–83

    Article  PubMed  Google Scholar 

  41. Ferrari A, Casanova M, Bisogno G, et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer 2003 May 15; 97 (10): 2597–604

    Article  PubMed  Google Scholar 

  42. Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 2004 Jan; 42 (1): 64–73

    Article  PubMed  CAS  Google Scholar 

  43. Orbach D, Rey A, Oberlin O, et al. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol 2005 Jul 1; 23 (19): 4363–71

    Article  PubMed  CAS  Google Scholar 

  44. Malempati S, Rodeberg DA, Donaldson SS, et al. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children’s Oncology Group. Cancer 2011 Aug 1; 117 (15): 3493–501

    Article  PubMed  Google Scholar 

  45. Defachelles AS, Rey A, Oberlin O, et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J Clin Oncol 2009 Mar 10; 27 (8): 1310–5

    Article  PubMed  Google Scholar 

  46. Merks JH, De Salvo GL, Bergeron C, et al. Parameningeal rhabdomyosarcoma: results of a pooled analysis from U.S. and European Cooperative Groups [abstract no. 9529]. J Clin Oncol 2011; 29 Suppl.: 9529

    Google Scholar 

  47. Lin C, Donaldson SS, Meza JL, et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803: a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys 2012; 82 (5): 1764–70

    Article  PubMed  Google Scholar 

  48. McDonald MW, Esiashvili N, George BA, et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2008 Nov 1; 72 (3): 884–91

    Article  PubMed  Google Scholar 

  49. Leseur J, Bernier V, Habrand J, et al. Intensity-modulated radiation therapy for pediatric head and neck rhabdomyosarcoma: French preliminary results [abstract no. 9549]. J Clin Oncol 2010; 28 (15 Suppl.): 9549

    Google Scholar 

  50. Cotter SE, Herrup DA, Friedmann A, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: Clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011; 81 (5): 1367–73

    Article  PubMed  Google Scholar 

  51. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012; 82 (2): 635–42

    Article  PubMed  Google Scholar 

  52. Martelli H, Haie-Meder C, Branchereau S, et al. Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience. J Pediatr Surg 2009 Jan; 44 (1): 190–6

    Article  PubMed  Google Scholar 

  53. Blank LE, Koedooder K, Pieters BR, et al. The AMORE protocol for advanced-stage and recurrent nonorbital rhabdomyosarcoma in the head-and-neck region of children: a radiation oncology view. Int J Radiat Oncol Biol Phys 2009 Aug 1; 74 (5): 1555–62

    Article  PubMed  Google Scholar 

  54. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993 Mar 1; 71 (5): 1904–22

    Article  PubMed  CAS  Google Scholar 

  55. Arndt C, Hawkins D, Anderson JR, et al. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 2004 May 15; 22 (10): 1894–901

    Article  PubMed  CAS  Google Scholar 

  56. Walterhouse D, Pappo AS, Meza JL, et al. Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): a report from the Children’s Oncology Group (COG) [abstract no. 9516]. J Clin Oncol 2011; 29 Suppl.: 9516

    Google Scholar 

  57. Walterhouse D, Pappo AS, Meza JL, et al. Vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): a report from the Children’s Oncology Group [abstract no. 9509]. J Clin Oncol 2012; 30 Suppl.: 9509

    Google Scholar 

  58. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence: results of the second study of the International Society of Paediatric Oncology — MMT84. Eur J Cancer 1998 Jun; 34 (7): 1050–62

    Article  PubMed  CAS  Google Scholar 

  59. Stewart RJ, Martelli H, Oberlin O, et al. Treatment of children with non-metastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol 2003 Mar 1; 21 (5): 793–8

    Article  PubMed  Google Scholar 

  60. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J Clin Oncol 2007 Feb 1; 25 (4): 362–9

    Article  PubMed  CAS  Google Scholar 

  61. Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2006 Jul 20; 24 (21): 3415–22

    Article  PubMed  Google Scholar 

  62. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2010 Oct 20; 28 (30): 4658–63

    Article  PubMed  CAS  Google Scholar 

  63. Rich TA, Kirichenko AV. Camptothecin radiation sensitization: mechanisms, schedules, and timing. Oncology (Williston Park) 1998 Aug; 12 (8 Suppl. 6): 114–20

    CAS  Google Scholar 

  64. Stevens M, Rey A, Bouvet N, et al. SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS) [abstract no. 8515]. J Clin Oncol 2004; 22 (14 Suppl.): 8515

    Google Scholar 

  65. Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004 Oct 1; 101 (7): 1664–71

    Article  PubMed  CAS  Google Scholar 

  66. Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 2008 Apr; 50 (4): 739–45

    Article  PubMed  Google Scholar 

  67. Weigel BJ, Lyden E, Anderson JR, et al. Early results from Children’s Oncology Group (COG) ARST0431: intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS) [abstract no. 9503]. J Clin Oncol 2010; 28 (15 Suppl.): 9503

    Google Scholar 

  68. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007 Dec; 49 (7): 928–40

    Article  PubMed  Google Scholar 

  69. Kang MH, Smith MA, Morton CL, et al. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011 Feb; 56 (2): 239–49

    Article  PubMed  Google Scholar 

  70. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010 Jul 1; 54 (7): 921–6

    PubMed  Google Scholar 

  71. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Jun; 50 (6): 1190–7

    Article  PubMed  Google Scholar 

  72. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011 Apr; 56 (4): 595–603

    Article  PubMed  Google Scholar 

  73. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Mar; 50 (3): 581–7

    Article  PubMed  Google Scholar 

  74. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Jul; 51 (1): 42–8

    Article  PubMed  Google Scholar 

  75. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010 Jul 15; 55 (1): 26–34

    PubMed  Google Scholar 

  76. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 Apr; 50 (4): 799–805

    Article  PubMed  Google Scholar 

  77. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 2011 Jul 20; 29 (21): 2933–40

    Article  PubMed  CAS  Google Scholar 

  78. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 2008 Jan 20; 26 (3): 399–405

    Article  PubMed  Google Scholar 

  79. Kuttesch Jr JF, Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer 2009 Oct; 53 (4): 590–3

    Article  PubMed  Google Scholar 

  80. Chisholm JC, Machin D, McDowell H, et al. Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma. Eur J Cancer 2007 Nov; 43 (17): 2537–44

    Article  PubMed  CAS  Google Scholar 

  81. Langevin AM, Bernstein M, Kuhn JG, et al. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 2008 Mar; 50 (3): 577–80

    Article  PubMed  Google Scholar 

  82. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, et al. Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 2006 Aug; 17 (7): 859–64

    Article  PubMed  CAS  Google Scholar 

  83. Geoerger B, Chisholm J, Le Deley MC, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer 2011 Jan; 47 (2): 230–8

    Article  PubMed  CAS  Google Scholar 

  84. Greenberg JA, Somme S, Russnes HE, et al. The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4′OH-tamoxifen. Cancer Res 2008 May 1; 68 (9): 3476–85

    Article  PubMed  CAS  Google Scholar 

  85. Oesch S, Walter D, Wachtel M, et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 2009 Jul; 8 (7): 1838–45

    Article  PubMed  CAS  Google Scholar 

  86. Pressey JG, Anderson JR, Crossman DK, et al. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2011 Dec 1; 57 (6): 930–8

    Article  PubMed  Google Scholar 

  87. Oue T, Yoneda A, Uehara S, et al. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 2010 Feb; 45 (2): 387–92

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Dr Walterhouse is a member of the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (STS COG) and study chair for COG ARST0331. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology/Stem Cell Transplant, Ann and Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, 225 E. Chicago, Box 30, Chicago, Illinois, IL 60611, USA

    Yasmin Gosiengfiao, Jennifer Reichek &  David Walterhouse

Authors
  1. Yasmin Gosiengfiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Reichek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Walterhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Walterhouse.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gosiengfiao, Y., Reichek, J. & Walterhouse, D. What is New in Rhabdomyosarcoma Management in Children?. Pediatr Drugs 14, 389–400 (2012). https://doi.org/10.1007/BF03262419

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262419

Keywords

Search

Navigation